Genetic Engineering News But the pharma giant is bracing for the loss of $5 billion in annual revenue as its patent on antidepressant Cymbalta® ( duloxetine hydrochloride) expires in December. The company's pipeline includes edivoxetine (LY2216684), an antidepressant in a Phase ...
7thSpace Interactive (press release) Methods: This is a post hoc analysis of two 13-week studies, in which patients were randomized to duloxetine 60 mg/day or placebo. Both studies allowed potential dose changes after 7 weeks of dosing, with Study I re-randomizing duloxetine treated ...
Healio Nearly 60% of patients who received an initial course of duloxetine reported reductions in pain associated with chemotherapy-induced peripheral neuropathy, according to study results. Painful chemotherapy-induced neuropathy occurs in 20% to 40% of ...
Seeking Alpha Cymbalta ( duloxetine ) is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for treating major depressive disorder and generalized anxiety disorder. Cymbalta, whose patent expires on December 11, 2013, accounted for $4.9 billion out of Eli Lilly ...
Genetic Engineering News But the pharma giant is bracing for the loss of $5 billion in annual revenue as its patent on antidepressant Cymbalta® ( duloxetine hydrochloride) expires in December. The company's pipeline includes edivoxetine (LY2216684), an antidepressant in a Phase ...
Genetic Engineering News But the pharma giant is bracing for the loss of $5 billion in annual revenue as its patent on antidepressant Cymbalta® ( duloxetine hydrochloride) expires in December. The company's pipeline includes edivoxetine (LY2216684), an antidepressant in a Phase ... and more »
7thSpace Interactive (press release) Methods: This is a post hoc analysis of two 13-week studies, in which patients were randomized to duloxetine 60 mg/day or placebo. Both studies allowed potential dose changes after 7 weeks of dosing, with Study I re-randomizing duloxetine treated ...
